RU2007116107A - Способы получения индазольных соединений - Google Patents

Способы получения индазольных соединений Download PDF

Info

Publication number
RU2007116107A
RU2007116107A RU2007116107/04A RU2007116107A RU2007116107A RU 2007116107 A RU2007116107 A RU 2007116107A RU 2007116107/04 A RU2007116107/04 A RU 2007116107/04A RU 2007116107 A RU2007116107 A RU 2007116107A RU 2007116107 A RU2007116107 A RU 2007116107A
Authority
RU
Russia
Prior art keywords
formula
compound
compounds
organic phase
reaction
Prior art date
Application number
RU2007116107/04A
Other languages
English (en)
Russian (ru)
Inventor
Бриджит Ли ЭВАНИКИ (US)
Бриджит Ли ЭВАНИКИ
Эрик Джон ФЛЭХИВ (US)
Эрик Джон ФЛЭХИВ
Анни Джудит КАСПАРЯН (US)
Анни Джудит КАСПАРЯН
Марк Брайан МИТЧЕЛЛ (US)
Марк Брайан МИТЧЕЛЛ
Майкл Дэвид ПЕРРИ (US)
Майкл Дэвид Перри
Стэйси Энн О`НИЛЛ-СЛАВЕККИ (US)
Стэйси Энн О`НИЛЛ-СЛАВЕККИ
Нил Уилль м САК (US)
Нил Уилльям САК
Джеймс Эдвард СЭНЗ (US)
Джеймс Эдвард Сэнз
Бин СИ (US)
Бин СИ
Небойс Слободан СТАНКОВИЧ (US)
Небойся Слободан СТАНКОВИЧ
Джа рам Кастури СРИРАНГАМ (US)
Джаярам Кастури СРИРАНГАМ
Цинпин ТЯНЬ (US)
Цинпин ТЯНЬ
Шу ЮЙ (US)
Шу ЮЙ
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. (US), Пфайзер Инк. filed Critical Пфайзер Инк. (US)
Publication of RU2007116107A publication Critical patent/RU2007116107A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
RU2007116107/04A 2004-11-02 2005-10-21 Способы получения индазольных соединений RU2007116107A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US60/624,635 2004-11-02
US71707105P 2005-09-14 2005-09-14
US60/717,071 2005-09-14

Publications (1)

Publication Number Publication Date
RU2007116107A true RU2007116107A (ru) 2008-11-10

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007116107/04A RU2007116107A (ru) 2004-11-02 2005-10-21 Способы получения индазольных соединений

Country Status (14)

Country Link
US (1) US7232910B2 (enExample)
EP (1) EP1809621A1 (enExample)
JP (1) JP2008518900A (enExample)
KR (1) KR20070058690A (enExample)
AR (1) AR051754A1 (enExample)
AU (1) AU2005300310A1 (enExample)
BR (1) BRPI0518203A2 (enExample)
CA (1) CA2586174A1 (enExample)
IL (1) IL182693A0 (enExample)
MX (1) MX2007005291A (enExample)
NO (1) NO20071619L (enExample)
RU (1) RU2007116107A (enExample)
TW (1) TWI294421B (enExample)
WO (1) WO2006048744A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252047B1 (en) * 2007-04-05 2022-05-11 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
PT2373640E (pt) 2009-01-08 2014-09-30 Merck Patent Gmbh Novas formas polimórficas do sal de cloridrato de 3-(1-{3- [5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-benzil}- 6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrilo e processos de fabrico das mesmas
WO2013046133A1 (en) 2011-09-30 2013-04-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
KR20140088556A (ko) 2011-11-11 2014-07-10 화이자 인코포레이티드 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
PL3077397T3 (pl) * 2013-12-06 2020-04-30 Vertex Pharmaceuticals Inc. Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
EP3127900B1 (en) * 2014-03-31 2017-10-18 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MX390878B (es) 2015-06-16 2025-03-21 Merck Patent Gmbh Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EA202192731A1 (ru) 2019-04-18 2022-02-04 Синтон Б.В. СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1613320A1 (en) * 2003-04-03 2006-01-11 Pfizer Inc. Dosage forms comprising ag013736
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor

Also Published As

Publication number Publication date
US20060094881A1 (en) 2006-05-04
KR20070058690A (ko) 2007-06-08
BRPI0518203A2 (pt) 2009-03-10
JP2008518900A (ja) 2008-06-05
TWI294421B (en) 2008-03-11
TW200621721A (en) 2006-07-01
CA2586174A1 (en) 2006-05-11
WO2006048744A1 (en) 2006-05-11
US7232910B2 (en) 2007-06-19
IL182693A0 (en) 2007-09-20
AR051754A1 (es) 2007-02-07
AU2005300310A1 (en) 2006-05-11
NO20071619L (no) 2007-04-25
EP1809621A1 (en) 2007-07-25
MX2007005291A (es) 2007-07-19

Similar Documents

Publication Publication Date Title
RU2007116107A (ru) Способы получения индазольных соединений
US10562904B2 (en) Synthesis process of ruxolitinib
EP3024833B1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
RU2010126906A (ru) Способ получения производного индолинона
RU2018100098A (ru) Полициклические соединения и способы их применения
KR970707129A (ko) β,β´-디하이드록시 메조-치환된 클로린, 이소 박테리오클로린, 박테리오클로린, 및 β,β´-비치환된 테트라피롤 매크로사이클로부터의 그 제조 방법(β,β´-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, BACTERIOCHLORINS, AND METHODS FOR MAKING THE SAME FROM β,β´-UNSUBSTITUTED TETRAPYRROLIC MACROCYCLES)
KR102586087B1 (ko) 다이아릴티오하이단토인 화합물의 제조 방법
RU2012150759A (ru) Пирроло[2,3-b]пиридиновые производные в качестве ингибиторов протеинкиназ
RU2015150728A (ru) Способ получения пиримидиновых производных
EA200500650A1 (ru) Способ получения (s,s)-цис-2-бензгидрил-3-бензиламинохинуклидина
CN106660935A (zh) 从5‑(卤甲基)糠醛产生化合物的方法
CA2515715A1 (en) Methods for producing cyclic benzamidine derivatives
JP2023078126A (ja) 光学活性ジアザスピロ[4.5]デカン誘導体の分割
Arnold et al. The preparation of pyrrole-2-carboxylates from vinyl sulfones
CN114853681A (zh) 一种嘧啶杂环脒基甲酸酯化合物的制备方法
Bates et al. Synthesis of sedamine by cycloisomerisation of an allenic hydroxylamine
JPS56125347A (en) Preparation of dipeptide
CN109134372A (zh) 一种吡啶并茚类化合物的制备方法
CN109020895B (zh) 一种金属催化的1-苄胺基取代苯并咪唑的合成方法
RU2008108089A (ru) Органические соединения
ES2664252T3 (es) Procesos para la síntesis de anillos heterocíclicos de cinco y seis miembros
TWI287016B (en) Process for preparing camptothecin
CN103254194B (zh) 一种8-硫杂黄嘌呤化合物的制备方法
RU2005127868A (ru) Новый способ получения метансульфоната 4-аминометил-3-алкоксииминопирролидина
CN114478388A (zh) 一种多官能团化的吡唑酮类化合物及制备方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090206